Targeted Nanoencapsulation of Tunicamycin Reduces Toxicity While Improving its Therapeutic Effectiveness in Pancreatic Cancer Cells Christopher.Koski@bruker.com Targeted Nanoencapsulation of Tunicamycin Reduces Toxicity While Improving its Therapeutic Effectiveness in Pancreatic Cancer Cells Read More »
Cross-reactive sarbecovirus antibodies induced by mosaic RBD-nanoparticles simplomarketing Cross-reactive sarbecovirus antibodies induced by mosaic RBD-nanoparticles Read More »
Responses to checkpoint inhibition in metastatic triple negative breast cancer driven by divergent myeloid phenotypes Christopher.Koski@bruker.com Responses to checkpoint inhibition in metastatic triple negative breast cancer driven by divergent myeloid phenotypes Read More »
Phenotypes and cytokines of NK cells in triple-negative breast cancer resistant to checkpoint blockade immunotherapy Christopher.Koski@bruker.com Phenotypes and cytokines of NK cells in triple-negative breast cancer resistant to checkpoint blockade immunotherapy Read More »
Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma Christopher.Koski@bruker.com Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma Read More »
Interleukin-27-polarized HIV-resistant M2 macrophages are a novel subtype of macrophages that express distinct antiviral gene profiles in individual cells: implication for the antiviral effect via different mechanisms in the individual cell-dependent manner Christopher.Koski@bruker.com Interleukin-27-polarized HIV-resistant M2 macrophages are a novel subtype of macrophages that express distinct antiviral gene profiles in individual cells: implication for the antiviral effect via different mechanisms in the individual cell-dependent manner Read More »
A Proteomics Outlook on the Molecular Effectors of CAR-T Cell Therapy in Cancer Management Christopher.Koski@bruker.com A Proteomics Outlook on the Molecular Effectors of CAR-T Cell Therapy in Cancer Management Read More »
A novel anti-HER2/EGFR bispecific antibody-drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs Christopher.Koski@bruker.com A novel anti-HER2/EGFR bispecific antibody-drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs Read More »
ZP4: A novel target for CAR-T cell therapy in triple negative breast cancer Christopher.Koski@bruker.com ZP4: A novel target for CAR-T cell therapy in triple negative breast cancer Read More »
Loss of LDOC1 by chromatin compaction in mesenchymal tumor cells is required for PFA1 ependymoma growth Christopher.Koski@bruker.com Loss of LDOC1 by chromatin compaction in mesenchymal tumor cells is required for PFA1 ependymoma growth Read More »
